Advertisement
Advertisement
U.S. Markets open in 3 hrs 16 mins
Advertisement
Advertisement
Advertisement
Advertisement

Diffusion Pharmaceuticals Inc. (DFFN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.53+0.78 (+11.56%)
At close: 04:00PM EDT
7.16 -0.37 (-4.91%)
After hours: 07:18PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.75
Open6.73
Bid0.00 x 1000
Ask0.00 x 1000
Day's Range6.56 - 7.53
52 Week Range5.10 - 43.00
Volume45,207
Avg. Volume87,849
Market Cap767.458M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.27
Earnings DateMar 15, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

    Completed Dosing in Altitude Trial; Topline Data Expected in June 2022Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable SecuritiesRegained Compliance with Nasdaq Bid Price Rule CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s abil

  • GlobeNewswire

    Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

    CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued

  • Benzinga

    Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow

    Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) will effect a 1-for-50 reverse stock split of its common stock. The reverse stock split is expected to become effective and commence trading on a post-split basis at the market's opening on April 19. Diffusion's reverse stock split was approved by the Company's stockholders at a special meeting earlier today. The Company expects that the split is part of its strategy to regain compliance with the $1.00 minimum bid price requirement of the Nasdaq Capit

Advertisement
Advertisement